Which has the lower trailing P/E, DXCM or TEVA?

DXCM has the lower trailing P/E: DXCM trades at 35.29 and TEVA at 62.70. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, DXCM or TEVA?

Over the past five years, DXCM grew revenue faster — DXCM at a 18.03% CAGR versus TEVA at 1.19%.

Is DXCM or TEVA more profitable?

DXCM runs the higher net margin — DXCM at 20.12% versus TEVA at 4.08%.

How have DXCM and TEVA total returns compared?

Over the past 10 years, DXCM delivered 14.62% and TEVA delivered -2.70% annualized total return. Past performance doesn't predict future results.

DexCom, Inc. (DXCM) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of DexCom, Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 28, 2026. Differences are shown without an overall score or investment verdict.

DXCM

DexCom, Inc.

$34.12B

$90.41HealthcareDelayed quote: Aug 28, 2026, 12:20 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$42.66B

$36.63HealthcareDelayed quote: Aug 28, 2026, 12:20 PM EDT

Total return — DXCM vs TEVA

growth of $100 · dividends reinvested · last 10y

DXCM +287.9% (+14.5%/yr)TEVA -23.4% (-2.6%/yr)DXCM compounded faster over this window

Log scale — wide-divergence pair

DXCM TEVA

DXCM vs TEVA: by the numbers

•TEVA is the larger company ($42.66B vs $34.12B market cap).
•DXCM trades at the lower trailing earnings multiple (35.29 vs 62.70 P/E), one valuation lens rather than an overall verdict.
•DXCM converts more revenue to profit (20.12% vs 4.08% net margin).
•DXCM grew revenue faster over the past five years (18.03% vs 1.19% CAGR).

Metrics side by side

Valuation

Metric	DXCM	TEVA
P/E ratio	35.29	62.70
Forward P/E	33.47	18.80
P/S ratio	7.04	2.57
P/B ratio	13.35	5.73
EV / EBITDA	25.14	19.40
FCF yield	4.02%	3.03%

Profitability

Metric	DXCM	TEVA
Gross margin	62.47%	52.47%
Operating margin	22.92%	11.45%
Net margin	20.12%	4.08%
ROE	38.14%	9.10%
ROIC	21.71%	6.79%

Growth (annualized)

Metric	DXCM	TEVA
Revenue CAGR (5Y)	18.03%	1.19%
EPS CAGR (5Y)	10.31%	N/A
FCF CAGR (5Y)	69.49%	14.58%
Total return CAGR (5Y)	-7.26%	32.11%

Frequently asked

Which has the lower trailing P/E, DXCM or TEVA?: DXCM has the lower trailing P/E: DXCM trades at 35.29 and TEVA at 62.70. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, DXCM or TEVA?: Over the past five years, DXCM grew revenue faster — DXCM at a 18.03% CAGR versus TEVA at 1.19%.
Is DXCM or TEVA more profitable?: DXCM runs the higher net margin — DXCM at 20.12% versus TEVA at 4.08%.
How have DXCM and TEVA total returns compared?: Over the past 10 years, DXCM delivered 14.62% and TEVA delivered -2.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full DXCM analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

DexCom P/E ratio Teva Pharmaceutical Industries P/E ratio DexCom ROE Teva Pharmaceutical Industries ROE DexCom operating margin Teva Pharmaceutical Industries operating margin DexCom revenue growth Teva Pharmaceutical Industries revenue growth DexCom free cash flow Teva Pharmaceutical Industries free cash flow

DexCom & Teva Pharmaceutical Industries appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 28, 2026.